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Background: The challenge of understanding factors inﬂ  uencing compliance with injectable 
treatments is critical as injectable biologics/medications become more common.
Objective: Understanding compliance issues for long term self-injectable treatments, using a 
chronic condition (osteoporosis) as a model.
Research design: A qualitative study to generate hypotheses regarding compliance issues for 
self-injectable treatments. Semi-structured interview guides were developed and data collected 
from patients and clinical experts. Findings were analyzed for common themes and a conceptual 
model of the compliance impact of self-injectable treatments generated.
Subjects: Six physicians (Rheumatology, Internal Medicine, and Endocrinology) and 22 
patients (14% never began treatment, 23% had ﬁ  lled at least one prescription but discontinued 
treatment, and 63% were currently on treatment) were interviewed.
Results: Physician and patient factors inﬂ  uenced the compliance process at four distinct time-
points: pre-treatment, time treatment recommended, short-term, and long-term. Physician 
factors that inﬂ  uenced patients’ persistence were knowledge about treatment, patient-training 
resources, and clinical proﬁ  le/efﬁ  cacy evaluations. For patients, motivation level, physician 
message, and clinical proﬁ  le were key. Logistical issues, minor side effects and injection site 
issues inﬂ  uenced adherence but not persistence.
Conclusions: Compliance is a multifactorial, dynamic process. Both physician and patient 
factors inﬂ  uence compliance at different points in the process.
Keywords: osteoporosis, self-injectable treatments, compliance, persistence, adherence
Introduction
The study of patient behavior regarding the taking of medications is not new (Dunbar-
Jacobs et al 2001) and has been called compliance and more recently adherence and/or 
persistence. For the purpose of this study, we have deﬁ  ned “compliance” as having 
two components: treatment persistence (continuing on treatment for the recommended 
duration) and adherence (taking treatment as prescribed, ie, the correct time of day or 
number of times per day). However labeled, there is little doubt that taking medication 
as prescribed and for the recommended time period is problematic for many patients 
and has signiﬁ  cant effects on health care outcomes and cost of care (Dunbar-Jacobs 
et al 2001; Piette et al 2004; Robiner 2005). A meta-analysis of 569 studies of adher-
ence to treatment found the average nonadherence rate to be 24.8% (DiMatteo 2004) 
and the overall difference between high and low adherence has been shown to be 26% 
(DiMatteo et al 2002). For persons with chronic disorders, as many as 60% may be 
poorly adherent to their prescribed medication (Dunbar-Jacobs et al 2001). Both low 
persistence and adherence rates limit the beneﬁ  ts of medical treatments (Haynes et al 
1996), impact the efﬁ  cacy proﬁ  le of a drug (Leo et al 2005), and present a challenge 
to prescribing physicians and their patients.Patient Preference and Adherence 2008:2 130
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The literature on compliance is extensive and addresses 
key issues of theory, factors that inﬂ  uence compliance and 
interventions to improve compliance (For reviews of the lit-
erature: Ryan 1999; Dunbar-Jacobs et al 2001; DiMatteo et al 
2002; McDonald et al 2002; Peterson et al 2003; DiMatteo 
2004). The factors that inﬂ  uence compliance are generally 
considered to be multivariate in nature and include patient 
characteristics, knowledge and beliefs about their illnesses as 
well as patient’s disease and treatment modality (DiMatteo 
2004; Schwartzman et al 2004; Leo et al 2005). Factors 
such as patients’ self-efﬁ  cacy (Fraser et al 2001), ethnicity, 
and number of daily prescribed pills (Graveley et al 1991), 
perceived severity of illness (Roberson 1992), complex-
ity of regimen (DiMatteo et al 1982), and cost (Piette et al 
2004) have all been found to play a role in compliance. For 
example, compliance with oral osteoporosis medications 
has been associated with patients’ recognition of the serious 
consequences of nonadherence, weighting of risks and ben-
eﬁ  ts and doubts about physicians’ competence to prescribe 
appropriate drugs (Unson et al 2003). Compliance has been 
found to be largely unaffected by age or demographic factors 
alone, although the data are sometimes contradictory (Ryan 
1999; DiMatteo 2004). Little attention has been paid to the 
role of the physician in inﬂ  uencing compliance.
The challenge of understanding factors that inﬂ  uence 
compliance with injectable treatments in a primary care set-
ting has become more critical as newer injectable biologics 
and medications for chronic illness prescribed in the primary 
care setting become more common (Mohr et al 2002). For 
injectable treatments, self injection is associated with better 
compliance than injection by a family member or by health 
professionals (Mohr et al 2002). Unfortunately, factors that 
inﬂ  uence compliance with self-injectable treatments are less 
well studied; although we do know that of women using a 
self-injectable treatment for contraception, only 42% are 
compliant at the end of one year and that side effects are cited 
as the main reason for treatment discontinuation (Beksinska 
et al 2001). In patients with multiple sclerosis, patients’ 
self-efﬁ  cacy, attitudes toward the disease and the treatment, 
sense of hope, perception of the physician as supportive as 
well as the interaction between the patient and the healthcare 
team strongly inﬂ  uence compliance with daily self-injectable 
treatments (Fraser et al 2001; Schwartzman et al 2004). For 
diabetics, daily injectable insulin regimes may be viewed as 
burdensome, although this burden appears to be attenuated 
by experience (Vijan et al 2005).
The purpose of this qualitative study was to further 
our understanding of adherence and persistence issues for 
self-injectable treatments in a primary care setting, primarily 
from the patient perspective. To do this, we conducted indi-
vidual or focus group interviews with patients for whom 
self-injectable treatments were prescribed. However, given 
that patients do not begin or continue on treatment without 
interactions with physicians, a limited number of individual 
interviews with physicians who prescribed self-injectable 
treatments (for patients other than those in the study 
sample) were also conducted. Based on the data gathered, 
a conceptual model of compliance for daily self-injectable 
treatments was developed. Teriparatide (Forteo®; Eli Lilly 
and Company, Indianapolis, IN, USA), a daily self-injectable 
treatment for osteoporosis, a condition diagnosed primarily in 
post-menopausal females, was used as the prototype therapy 
condition for the study.
Methods
Data collection
First, the relevant peer-reviewed journal literature on 
osteoporosis, self-injectable treatment and compliance was 
reviewed to identify potential issues that may inﬂ  uence com-
pliance from both the patient and the physician’s perspective. 
Based on this review, two semi-structured interview guides 
regarding compliance issues for a daily self-injectable 
treatment were developed: one tailored for physicians who 
prescribed teriparatide, and one tailored for patients who 
were prescribed teriparatide. The patient interview guide 
asked about their expectations regarding a self-injectable 
treatment prior to initiating the treatment, the education/train-
ing they received, factors they believed affected their daily 
use of medication as prescribed, continued use over time, 
reasons for discontinuation, and any mediating factors which 
might have inﬂ  uenced their treatment behaviors. The physi-
cian interview guide asked similar questions and asked the 
physician to respond according to both how they felt about 
these issues as well as how they perceived that their patients 
felt. All interviews were conducted by the same trained 
professional. Ethics committee approval was obtained for 
the study and patients gave informed consent.
Sample
To identify the patient sample, physicians who had experi-
ence with teriparatide were identiﬁ  ed from an Information 
Management System (IMS) database of physicians who 
had prescribed teriparatide or were known to the authors 
as treating osteoporosis as a major component of their 
practice. The physicians identiﬁ  ed were contacted by the 
ﬁ  rst author, starting with those physicians who had the Patient Preference and Adherence 2008:2 131
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greatest experience with prescribing teriparatide in each of 
3 specialties (Rheumatology, Endocrinology, and Internal 
Medicine), were from varied geographic areas and were both 
academic and community-based physicians. Physicians were 
asked to participate in the study by identifying and recruiting, 
from their patient populations, a sample of three groups of 
patients: 1) those that had been recommended teriparatide 
but had chosen not to initiate treatment, 2) those that initiated 
treatment but did not complete the recommended course of 
treatment, or 3) individuals who initiated treatment and were 
currently on teriparatide. These patients were interviewed fol-
lowing the discussion guide in either an individual telephone 
interview (lasting approximately one hour) or in a focus group 
setting (lasting approximately three hours). The focus groups 
were audio-taped and transcribed. Each physician was then 
individually interviewed by telephone for approximately one 
hour following the semi-structured interview guide.
Data analysis
The qualitative data (transcripts, written notes) from both the 
physicians and the patients were analyzed by the ﬁ  rst author 
for commonality of concepts regarding compliance issues. 
These commonalities were grouped into themes which were 
then categorized as important for either adherence or persis-
tence and for when in the treatment process they exerted their 
inﬂ  uence (ie, start of treatment, during treatment). Based on 
the common themes, a conceptual model of the impact of 
treatment on compliance was developed.
Results
Sample
Twenty-two patients (21 women, 1 man), age range 42–88 
years old (mean age 72), were interviewed. Eight of these 
patients were interviewed individually by telephone and 14 
participated in one of two focus groups (Florida or Cleve-
land). The mean length of time with osteoporosis was nine 
years and most (55%) felt their condition was severe, they had 
suffered a previous fracture (68%) or considered themselves 
at risk for a future fracture (77%). Three (14%) of the subjects 
(2 women, 1 man) never began treatment with teriparatide 
even though their physicians recommended or prescribed it. 
Five (23%) of the woman ﬁ  lled at least one prescription but 
discontinued sometime during the course of treatment, and 14 
(63%) of the woman were currently on treatment. Half of the 
sample was either married (41%) or had a partner (9%) and 
half were widowed (36%), divorced (9%) or single (5%). The 
majority were Caucasian (90%) with an average household 
income (59%) of US$20,000 to $60,000.
Six physicians, located in San Francisco, Cleveland, New 
York, and Florida, were interviewed. The physicians were 
practicing in the specialties of Rheumatology (2), Internal 
Medicine (2), and Endocrinology (2). Two physicians prac-
ticed in an academic setting and the remaining four practiced 
in a community setting. These experts had practiced an 
average of 19 years (range 5–30) and wrote an average of 
20 teriparatide prescriptions a year (range 4–45).
Conceptual model
Based on the findings from the physician and patient 
interviews, a conceptual model of compliance with a self-
injectable medication was developed (Figure 1).
Precursor factors inﬂ  uencing compliance
Physician knowledge about teriparatide was the key factor 
that determined whether or not the physician prescribed 
teriparatide and, if so, how the treatment was presented 
to the patient. This knowledge was shaped by their beliefs 
about the efﬁ  cacy of the treatment, comfort with the available 
clinical data and their assessment of severity and incidence 
of side effects. The self-reported level of knowledge regard-
ing teriparatide varied among physicians and several desired 
additional information on the efﬁ  cacy and/or long-term safety 
data. There was also some confusion over the appropriate 
treatment after patients completed the recommended 18–24 
month treatment course. These types of issues contributed 
to their hesitancy in prescribing the treatment. Physicians 
commented that “I don’t prescribe [this drug] because … it 
may be a short-term ﬁ  x for this population … not convinced 
by data as N is too small.”
A second factor that inﬂ  uenced physicians’ decision to 
recommend teriparatide was their ability and/or resources 
to train the patients on a self-injectable medication. As one 
physician stated, “This drug requires more explanation and 
time for an ofﬁ  ce … a busy doctor may not have the patience 
or time that is needed to prescribe. Specialists can spend more 
time.” Additionally, issues regarding reimbursement and 
coverage were not clearly understood by physicians. Cost 
was considered an obstacle to prescribing as some ofﬁ  ces did 
not have the resources to advocate coverage assistance for 
patients. In spite of these barriers to prescribing, physicians 
who did recommend teriparatide felt enthusiastic about the 
treatment as they gained more experience with the product.
Decision to initiate treatment
Both physicians and patients agreed that the patient’s motivation 
(based on perception of severity of their osteoporosis, previous Patient Preference and Adherence 2008:2 132
Brod et al
fracture history, fear of future fractures, and/or availability of 
alternative treatments) was a key factor inﬂ  uencing a patient’s 
decision to begin treatment and remain treatment-persistent. As 
one physician commented, “Those who stay on it [teriparatide] 
have either experienced pain of fracture or are fearful of bone 
health in the future and so are very motivated … (they) are 
looking over the cliff and know that they don’t have enough 
bone to continue.” This sentiment was also often expressed 
by patients who felt that, “If you think your osteoporosis is 
bad enough, you’ve had some fractures … you try anything.” 
Patients weighed the potential risk of treatment (ie, teriparatide 
has a black box warning that in rat studies there is a duration 
and exposure relationship of therapy and bone sarcoma) 
against the beneﬁ  ts of treatment (ie, reduction in the risk of 
facture). Patients indicated they were more willing to accept 
the potential risks if they were highly motivated and had initial 
expectations of successful treatment.
The physician’s message to the patient and their level of 
enthusiasm for the treatment was another key factor inﬂ  uencing 
whether or not the patient accepted the treatment suggestion. 
One endocrinologist, who considered herself very familiar with 
the drug and wrote between 40–50 prescriptions a year felt that 
the “average doc does not know the data and can’t be passionate 
about it … (and this greatly inﬂ  uenced prescribing patterns).” 
Finally, cost could also be a major deterrent to patients starting 
treatment if they could not arrange payment coverage from 
their health care insurer or did not believe they could access the 
company-funded patient assistance program.
Both patients and physicians felt that patient fear of 
injection or having a previous negative experience with self 
injection were not major deterrents to accepting treatment, 
especially after patients saw the injection pen. One of the 
physicians commented, “I use the demo pen for the ﬁ  rst time 
and show them exactly how to do it … this really helps. If 
(patient) decides to go on then we schedule a real training … 
makes a difference.” However, the absence of adequate staff or 
resources to train patients was problematic for many ofﬁ  ces.
Factors inﬂ  uencing short-term 
compliance (the ﬁ  rst month of treatment)
Patients agreed that the ﬁ  rst month of treatment was a critical 
time frame for resolving factors that determined whether or 
not they remained on treatment and that simply receiving the 
prescription without continued encouragement and support 
was problematic. Physicians agreed that this support was 
important. As one endocrinologist emphasized, “Doctors 
must work with patients to get them to follow through (with a 
self-injectable treatment). This is not just writing a script.”
Problems with self-injecting that occurred within the ﬁ  rst 
few weeks of starting treatment could be ameliorated by the 
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physician or their staff. Most patients who were given this 
support were able to work through their difﬁ  culties. However, 
the ability to provide adequate training or follow-up support 
to patients varied among ofﬁ  ces. Ofﬁ  ces that had one-on-one 
training where patients practiced self injecting in the ofﬁ  ce 
and/or had a protocol where a patient was followed up soon 
after starting treatment reported fewer compliance issues than in 
ofﬁ  ces with poorer self-injection training and little or no follow 
up. The optimal training scenario seemed to be one described 
by one of the physicians, “(we) have a clinical protocol to teach 
technique … then (we) call the patient a few days later to see 
how they are doing … a high percentage of patients have contact 
with the ofﬁ  ce within the ﬁ  rst week. Then everyone is brought 
back at three months … (we) don’t spend a lot of time but if they 
have technical problems with (the) shot … they go to the nurse 
to address … seems to make a difference.” Additionally, written 
and visual instructions helped women gain proper experience 
and conﬁ  dence when injecting at home for the ﬁ  rst few times. 
One patient commented, “It took me a while to get the steps 
going. Every time I did it I’d have to take out the instructions and 
read them … And I think it was like three or four weeks before I 
didn’t need that paper anymore. And I just used it to make sure 
I got it right. And then one day I’d forgotten the paper and just 
did it. So I said, ‘well, I can do it now.’ But it did take a while, 
because I think it’s kind of stressful.” Most patients agreed that 
after about a month of self-injection they became much more 
conﬁ  dent and comfortable with the injection process.
The most common reasons for stopping treatment in 
the ﬁ  rst few weeks were side effects such as severe rash or 
dizziness. Both patients and physicians agreed that this was 
a sufﬁ  cient reason to end treatment without further interven-
tions. Nonserious side effects did not impact compliance. For 
example, as one patient commented, “So after you’ve spent 
six weeks in a hospital because of [a] fracture … you’re will-
ing to do most anything to avoid that again. [Being] a little 
nauseous in the middle of the night is nothing like being in 
the hospital for close to two months.”
Factors inﬂ  uencing long-term 
persistence (from one month to end 
of recommended treatment)
Long-term persistence was most strongly inﬂ  uenced by 
perceived treatment efﬁ  cacy over time. For some patients, 
efﬁ  cacy was judged by their experience. As one patient said, 
“If I fall now, I don’t break anything … before that I had 
broken wrists.” Others evaluated efﬁ  cacy by a repeat test for 
bone mineral density (BMD). As one patient noted, “What 
I’m unhappy about is the fact that after taking it for seven 
months … it showed absolutely no change … So my plan 
is to stop it … For that much money I wanted to see at least 
some kind of change, and there wasn’t really anything.”
Patients’ decision to stay on treatment after poor BMD 
results or a new fracture experience was tempered by their 
initial expectations of the drug. Those who expected a “miracle 
cure” were more likely to be disappointed and discontinue 
treatment. A common sentiment was, “once you take [the drug] 
it’s supposed to ﬁ  x everything … you know, everything will 
go back into place.” An initial enthusiastic physician message 
sometimes backﬁ  red when extreme efﬁ  cacy expectations were 
not met. As one patient put it, “[My] physician said, ‘I’m so 
thrilled because we’re now going to accomplish something 
and hopefully you’re not going to break any more ribs.’ He 
was really excited about it and anxious to start on it. He really 
thought it was going to be great and I wouldn’t have so many 
breaks and [that] we had ﬁ  nally found an answer to this. And 
it didn’t turn out that way.” In contrast to this, another patient, 
who had not seen any improvement on a previous treatment, 
was simply happy to have another option. In spite of “injections 
sometimes hurtful … [and] occasional reactions …. [felt that] 
I’m still handling it” and intended to stay on treatment.
Factors inﬂ  uencing adherence
Of those women who continued on treatment, most felt that they 
were very adherent (more than 95% of time as prescribed). Many 
patients experienced occasional bruising or pain from injections, 
minor side effects or difﬁ  culties using the injection pen over 
the course of their treatment. Concerns about proper injection 
procedure (priming the pen properly, refrigeration issues and 
travel issues) continued over time. These difﬁ  culties were viewed 
as inconveniences rather than factors determining persistence. 
However, this did not impact adherence. For example, one patient 
noted, “I bruise easily … probably get a bruise every 10 times 
that I give it [to myself]. No, I would not consider stopping it 
… it is not a big deal.” Concerns and difﬁ  culties with traveling 
with teriparatide (refrigeration issues, carrying the pen through 
security) were common and also impacted adherence. Many 
patients commented that, “When I travel … I was out of my 
routine … so I forgot it … [or] because I don’t want to have to 
deal with it.” These problems generally did not get addressed 
with a health care professional due to limited physician follow 
up after initiating treatment or patient reluctance to bring up these 
perceived “minor” problems or worries to their physician.
Discussion
This study found that both physician and patient factors 
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Brod et al
distinct decision points that inﬂ  uence compliance behavior: 
pre-initiation of treatment, at the time treatment is recom-
mended to the patient, the short-term period (the ﬁ  rst month 
of treatment) after a prescription is given and in the long term. 
Of note is that the ﬁ  rst decision point actually occurs even 
before the patient is seen by the physician and is inﬂ  uenced 
by the physician’s beliefs and knowledge about the treat-
ment. These pre-initiation of treatment factors inﬂ  uence how 
treatment is presented to the patient and helps “set the stage” 
for future patient compliance behaviors and attitudes. Thus, 
these precursor factors should be considered in understanding 
the broader factors which inﬂ  uence patient compliance over 
time. When the treatment is discussed with the patient, it is 
this degree of physician comfort with the treatment that will 
determine the “enthusiasm” by which the treatment option is 
presented to the patient. This initial message to the patient 
will, in turn, strongly inﬂ  uence the patient’s decision as to 
whether she or he actually accepts and ﬁ  lls the prescription 
and remains treatment persistent.
The key patient factors that were found to inﬂ  uence the 
decision to initiate treatment were patient motivation and 
initial expectations about treatment. Once treatment was 
initiated, the key patient factor inﬂ  uencing compliance in the 
short term was the training given to the patient for self inject-
ing and/or the occurrence of serious side effects. Serious side 
effects were generally not an inﬂ  uence in the long term. After 
approximately the ﬁ  rst month of treatment, the next critical 
decision point affecting persistence occurred once treatment 
effectiveness could be evaluated. Patients who did not see 
a signiﬁ  cant improvement felt very discouraged and were 
more likely to discontinue treatment despite encouragement 
from their physicians. In general, short-term persistence was 
heavily inﬂ  uenced by physician factors whereas long-term 
persistence was heavily inﬂ  uenced by patient factors.
Factors that inﬂ  uenced adherence were different than 
those that inﬂ  uenced persistence. “Convenience factors,” 
such as ease of travel with the medication and minor injection 
site issues, continued to affect compliance behavior over the 
course of treatment.
Inﬂ  uential factors were not constant over the course of 
treatment. Thus, compliance should be considered a dynamic 
(constantly changing), ongoing process with different fac-
tors inﬂ  uencing adherence and persistence and at different 
points in the process. Just as other studies have found variable 
compliance rates depending upon the deﬁ  nition used and/or 
the method of assessing compliance (Dunbar-Jacob et al 
2001; DiMatteo et al 2002; DiMatteo 2004), so will differ-
ences in factors inﬂ  uencing compliance vary by where in the 
time course of treatment they are examined and whether it 
is persistence or adherence that is of issue. Interventions to 
improve compliance should address all of the social factors, 
regimen characteristics and system issues (Robiner 2005) that 
were identiﬁ  ed in this study. By understanding the dynamic 
and interacting nature of these factors, more targeted inter-
ventions can be developed to help improve compliance with 
the increasing number of self-injectable treatments.
The perception that the physician is supportive and 
knowledgeable of the treatment has been found to be one of 
the signiﬁ  cant predictors of compliance in a chronic disease 
such as osteoporosis (Fraser et al 2001; Unson et al 2003), as 
well as for psychiatric treatments (Bourgeois 2005; Leo et al 
2005). This study conﬁ  rmed the important role that physi-
cians/health care providers play in inﬂ  uencing both adherence 
and persistence. The physician/health care provider message, 
including level of enthusiasm for the treatment, played a 
key role in determining if the patient would initially accept 
the treatment or remain persistent in the ﬁ  rst few weeks. 
This physician message was in turn highly inﬂ  uenced by 
the physician’s comfort with the treatment and knowledge 
about its efﬁ  cacy. For a new treatment just becoming avail-
able, particular attention should be given to educating and 
informing physicians as to the potential of the treatment, 
including its limitations. Uninformed or ill-informed health 
care providers may unintentionally provide a “less than 
enthusiastic” or an “overly inﬂ  ated expectation” message to 
their patients regardless of the efﬁ  cacy of a new treatment. 
Physician enthusiasm which sets unrealistic high patient 
expectations may have contributed to some patients being 
discouraged with the degree of their long-term improvement 
and resulted in premature treatment discontinuation.
A major predictor of adherence may be the patient’s 
perception of the burden of treatment (Vijan et al 2005). Con-
trary to some common wisdom, patients’ fear of self injection 
was not found to be a major burden in either persistence or 
adherence. This ﬁ  nding is supported by similar ﬁ  ndings with 
self-injectable treatments for diabetes, where the greatest 
number of barriers to adherence was in the dietary and exer-
cise realms rather than with insulin injection (Glasgow et al 
1986). Also of interest was the ﬁ  nding that many of these 
patients did not know how to properly evaluate the efﬁ  cacy 
of the treatment and were disillusioned with the treatment 
when their expectations of beneﬁ  t were not met. This is 
particularly problematic for a condition like osteoporosis 
where markers of long-term beneﬁ  t are sometimes confusing 
as lumbar spine BMD has been found to be a poor predictor 
of vertebral fracture risk after treatment (Cummings et al Patient Preference and Adherence 2008:2 135
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2002; Sarkar et al 2004). This may also present a problem 
for other chronic conditions where self injection is common. 
For example, multiple sclerosis patients may confuse the 
relapsing-remitting nature of a disease with lack of treat-
ment efﬁ  cacy. Similarly for diabetics, the absence of current 
complications which may take many years to manifest may 
be confused with treatment success. In such circumstances, 
patient education regarding expected beneﬁ  ts and improved 
understanding of how to judge treatment efﬁ  cacy should help 
improve both adherence and persistence with treatment.
It was not the purpose of this study to examine differences 
and similarities between patient and physician perceptions 
regarding compliance. However, some interesting differences 
were noted. Although both physicians and patients agreed 
that patient motivation was key to successful treatment, phy-
sicians might be underestimating their inﬂ  uence in motivating 
patients and shaping their expectations regarding treatment 
outcomes. Additionally, patients may have a greater need 
for ongoing support and access to information to ongoing 
questions and issues than is anticipated or available from 
many health care ofﬁ  ces. It is hoped that future research can 
more directly address the issues of similarities and differ-
ences between physician and patient perspectives and their 
impact on compliance.
Caution should be used in generalizing the ﬁ  ndings of 
this study to models of compliance for other self-injectable 
treatments. The study used a convenience sample and all but 
one of our participants were female. The persistence rate of 
our sample (65%) was also higher than generally reported in 
the literature (Dunbar-Jacob et al 2001; DiMatteo et al 2002; 
DiMatteo 2004). Our sample was also older, predominately 
Caucasian, and retired. Thus our model may be disease, treat-
ment, gender and/or sample dependent. However, the wide 
age range and geographic distribution of the sample should 
help improve the generalizability of our ﬁ  ndings. Continued 
research is necessary to conﬁ  rm or adapt our model for other 
conditions with their respective treatments and it is hoped 
that this study will further the generation of new hypotheses 
on which these future studies can collect quantitative data 
more suitable for statistical testing. Finally, although the 
purpose of this study was not to enter the debate on the cor-
rect labeling of medication behavior as compliance, adher-
ence or persistence, we do believe that a common language 
and deﬁ  nition of terms is necessary if we are to be able to 
accurately report and further our understanding of the role 
of medication behavior. Differences in deﬁ  ning compliance 
terms may account for some of the variability in estimates 
found in the literature. Given that one can be persistent 
and yet not adherent, we suggest that the two concepts be 
addressed separately under a broader umbrella of compliance. 
Further, uniformity in methods of assessing each aspect of 
compliance would greatly facilitate the interpretation of 
much of the literature. However labeled or measured, it 
remains clear that compliance is a key factor in determining 
the overall effectiveness of treatments.
Conclusions
Based on the ﬁ  ndings from this study, the following basic 
principles of compliance were formulated:
•  Compliance is a process over time that is inﬂ  uenced by 
both physician and patient factors.
•  This process begins BEFORE the patient is prescribed 
the treatment.
•  Physician factors (such as physician level of comfort with 
a treatment’s safety and efﬁ  cacy) play a key role in the 
physician’s decision to prescribe a treatment.
•  The physician’s message (level of enthusiasm) conveyed 
to the patient AND the type of training received by the 
patient are major factors in determining if the patient will 
actually start treatment.
•  Physician support and continued enthusiasm for the treat-
ment during the ﬁ  rst weeks of treatment plays a key role 
in compliance at the start of treatment.
• Perceived  efﬁ  cacy on the part of the patient is a key factor 
for long-term persistence.
•  Factors that inﬂ  uence adherence differ from factors that 
inﬂ  uence persistence.
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